Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
aTyr Pharma, Inc. LIFE
$2.35
+$0.01 (0.21%)
На 18:01, 12 мая 2023
+368.09%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
126525798.00000000
-
week52high
4.28
-
week52low
1.56
-
Revenue
10386000
-
P/E TTM
-1
-
Beta
1.22179900
-
EPS
-1.68000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 16 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 21 июл 2022 г. |
| Piper Sandler | Overweight | Overweight | 18 мая 2022 г. |
| RBC Capital | Outperform | Outperform | 10 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Shukla Sanjay | A | 50798 | 10000 | 21 ноя 2022 г. |
| Shukla Sanjay | A | 40798 | 15000 | 01 июл 2022 г. |
| DENYES NANCY | A | 88097 | 88097 | 24 мая 2022 г. |
| Broadfoot Jill Marie | A | 75347 | 75347 | 24 мая 2022 г. |
| Shukla Sanjay | A | 516280 | 516280 | 24 мая 2022 г. |
| Zaknoen Sara | A | 6000 | 6000 | 26 апр 2022 г. |
| SCHIMMEL PAUL | A | 6000 | 6000 | 26 апр 2022 г. |
| Lucas Svetlana | A | 6000 | 6000 | 26 апр 2022 г. |
| Gross Jane A | A | 6000 | 6000 | 26 апр 2022 г. |
| COUGHLIN TIMOTHY | A | 6000 | 6000 | 26 апр 2022 г. |
Новостная лента
aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
GlobeNewsWire
11 мая 2023 г. в 16:00
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference, which is scheduled to take place May 16 – 17, 2023, in New York, NY.
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 18:20
Atyr Pharma (LIFE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.44 per share a year ago.
aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript
Seeking Alpha
10 мар 2023 г. в 17:12
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Relations & Corporate Communications Sanjay Shukla - President & Chief Executive Officer Jill Broadfoot - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Sara Nik - H.C. Wainwright Yale Jen - Laidlaw Operator Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma Fourth Quarter and Full Year 2022 Conference Call.
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 18:19
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma to Present at March Investor Conferences
GlobeNewsWire
08 мар 2023 г. в 08:00
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at two upcoming investor conferences scheduled to take place in March 2023.